Avacopan for the Treatment of ANCA-Associated Vasculitis
- 18 February 2021
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (7), 599-609
- https://doi.org/10.1056/nejmoa2023386
Abstract
The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis.Keywords
This publication has 29 references indexed in Scilit:
- Lymphopenia and Treatment-Related Infectious Complications in ANCA-Associated VasculitisClinical Journal of the American Society of Nephrology, 2013
- Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody DiseaseClinical Journal of the American Society of Nephrology, 2012
- Assessment of health‐related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's)Arthritis Care & Research, 2011
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Overall survival, renal survival and relapse in patients with microscopic polyangiitis: a systematic review of current evidenceRheumatology, 2011
- Wegener's granulomatosis in Finland in 1981–2000: risk of dialysis-dependent renal diseaseScandinavian Journal of Rheumatology, 2011
- Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuriaNature Biotechnology, 2007
- Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitisArthritis Care & Research, 2003
- Evidence‐based treatment of systemic vasculitisRheumatology, 2000
- Anti-Neutrophil Cytoplasmic Autoantibodies with Specificity for Myeloperoxidase in Patients with Systemic Vasculitis and Idiopathic Necrotizing and Crescentic GlomerulonephritisThe New England Journal of Medicine, 1988